Mayne Pharma Group

Mayne Pharma Group (MYX)

Stock Code

MYX

Stock Exchange

ax

Mayne Pharma (MYX) was known as FH Faulding & Co where amongst other activities including pharmaceutical wholesaling and consumer health products, it built success around optimising the delivery of oral dosage form drugs. In 2001, Mayne Group Ltd acquired FH Faulding & Co and then in November 2005, Mayne Group Ltd demerged the business. MYX was listed on the Australian stockmarket (ASX) on 29 June, 2007.

Mayne Pharma Limited

A global pharmaceutical company focused on research and development, manufacture, marketing and distribution of injectable and oral pharmaceuticals; and

Mayne Pharma $1.6m Profit 1H2013


Drug manufacturing company, Mayne Pharma Group (ASX:MYX) have announced its half year financial results for 2013 to its shareholders and investors on the Australian stock market.

  • Mayne Pharma announced a NPAT (Net Profit After Tax) excluding non-recurring items of $1.6 million.
  • MYX also reported sales revenue of $27 million and NPAT of $2.5 million loss.
  • Mayne Pharma EBITDA was $1.2m with underlying EBITDA at $5.4 million.
Syndicate content

Recommended Websites